Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
02. Oktober 2024 06:00 ET
|
Liquidia Corporation
Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
11. September 2024 08:26 ET
|
Liquidia Corporation
Liquidia Corporation announces raise of $67.5M.
Liquidia to Present at Upcoming Investor Conferences
28. August 2024 08:00 ET
|
Liquidia Corporation
Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September.
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
19. August 2024 06:00 ET
|
Liquidia Corporation
The FDA has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with PAH and PH-ILD.
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
03. Juni 2024 07:00 ET
|
Liquidia Corporation
Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics that sought to block the launch of Liquidia’s YUTREPIA™.
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
13. Mai 2024 17:43 ET
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024.